Policy Updates

Limited evidence exists that supports the use of most circulating tumor DNA assays in the diagnosis or management of early-stage or advanced solid tumors, according to an expert review.
New recommendations from the Hematology/Oncology Pharmacy Association (HOPA) support dose-rounding of up to 10% for biologic and cytotoxic anticancer agents.
The American Society of Clinical Oncology as endorsed other professional societies’ molecular guidelines on selecting patients with lung cancer for treatment with targeted tyrosine kinase inhibitors.
Pointing to the potential usefulness of genetic tests and therapeutics in patient care, the American Medical Association is calling for greater transparency and more standardized guidelines for payer coverage.
The National Comprehensive Cancer Network is partnering with a health care decision support company to integrate their clinical practice guidelines into a technological resource for point-of-care access and treatment recommendations.
A new clinical pathway has been designed and implemented to improve colon and rectal surgical procedures and enhance successful patient recovery.
McKesson Specialty Health and The US Oncology Network have expanded their agreement with the National Comprehensive Cancer Network to add five new disease states to Value Pathways.
The NCQA has launched a new Oncology Medical Home Recognition program, which provides a framework for using clinical pathways and quality improvement measures in the patient-centered medical home.
In a new policy statement, ASCO states that well-designed clinical pathways should be the first choice of payers, while cautioning that other health utilization strategies for cancer drugs may limit patient access.
New guidelines have been created involving urology and radiation strategies for the treatment of non-metastatic muscle-invasive bladder cancer.